Developer docs
API playgroundTry for free, no card

Search company profiles

Naobios

Full company profile

uuid00032ae

Namestring
Naobios
Legal namestring
NAOBIOS
Websiteurl
naobios.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Naobios is a France-based Contract Development and Manufacturing Organization (CDMO) headquartered in Saint-Herblain near Nantes, specializing in bioprocess development and GMP-compliant contract manufacturing of virus-based products for preclinical and clinical use. The company serves pharmaceutical and biotechnology companies, academic institutions, and public health agencies worldwide, with a portfolio spanning viral vaccines (live and inactivated), viral vectors, oncolytic viruses, exosomes, and Human Viral Challenge Agents (HVCAs). Naobios operates as a subsidiary of the Clean Biologics group, alongside its sister company Clean Cells, which provides complementary in-process and release testing services.

The company's core technical platform encompasses upstream processing (USP) and downstream processing (DSP) for virus-based biologics, utilizing adherent cell-based processes (Vero, MRC5, BHK21, CEF with microcarriers, fixed bed reactors, roller bottles) and suspension cell lines (CAP, EB66, CHO). Manufacturing scales extend up to 200L in stirred tank reactors or 200m² in fixed bed bioreactors, and Naobios operates both BSL2 and BSL3 GMP suites, including a 110 sqm BSL3 facility designed per French decree and EU-GMP standards. The company has manufactured and released 36 GMP batches of HVCAs covering SARS-CoV-2, RSV, hMPV, and influenza, alongside 55+ GMP drug substance batches, and can deliver a drug product within 11 months using an in-house developed process. Regulatory credentials include ANSM pharmaceutical establishment licensing (authorization F19/219), EU-GMP certification, and authorization for GMO handling.

Naobios generates revenue through project-based B2B service contracts for bioprocess development, GMP manufacturing, quality control testing, and regulatory support, supplemented by grant funding from organizations such as the Bill & Melinda Gates Foundation. Pricing is quote-based and project-specific, depending on scope, scale, biosafety level, and regulatory requirements, and is not publicly disclosed. Business development is led by a dedicated manager conducting direct enterprise outreach, supported by content marketing (whitepapers, webinars), industry conference participation, and LinkedIn remarketing targeting pharmaceutical and biotech professionals globally.

Short descriptiontext

Naobios is a France-based CDMO providing bioprocess development and GMP manufacturing services for virus-based products—including viral vaccines, viral vectors, oncolytic viruses, and human viral challenge agents—to pharmaceutical, biotech, academic, and public health clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaint-herblain, France
HQ citystring
Saint-herblain
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
viral vaccine manufacturing, bioprocess development services, GMP contract manufacturing, viral vector production, oncolytic virus CDMO
Industry3 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Viral Biologics Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services (CDMO)
TypeProfessional Services
Description

Naobios provides bioprocess development and GMP contract manufacturing services for preclinical and clinical batches of virus-based products (viral vaccines, viral vectors, oncolytic viruses, challenge agents). Revenue is generated through project-based contracts with pharmaceutical/biotech clients, academic institutions, and health agencies. The company handles process and analytical development, production of preclinical material, GMP manufacturing, QC release testing, and regulatory support under service agreements.

naobios.com
2Grant Funding
TypeProfessional Services
Description

Naobios receives grant funding from foundations (e.g., Bill & Melinda Gates Foundation) to support vaccine development projects, specifically for manufacturing human viral challenge agents for CHIM studies and evaluating vaccine effectiveness in low- and middle-income countries.

finsmes.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Naobios is a GMP-certified Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and contract manufacturing services for virus-based products, including viral vaccines (live and inactivated), viral vectors, oncolytic viruses, exosomes, and Human Viral Challenge Agents. The company delivers end-to-end services spanning upstream and downstream bioprocess development, GMP manufacturing of preclinical and clinical batches, and quality control testing, with full BSL2 and BSL3 capabilities supporting manufacturing up to 200L stirred-tank or 200m² fixed-bed bioreactor scale.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Drug product delivery in 11 months using in-house developed process
+2 more records
Product overview1 text field

Naobios is a Contract Development and Manufacturing Organization (CDMO) providing a comprehensive suite of virus-based products and services. The product portfolio includes Live Viruses, Oncolytic Viruses, Exosomes, Inactivated Viruses, and Human Viral Challenge Agents. These products are supported by integrated services covering Bioprocess Development (USP/DSP), GMP Biomanufacturing (cell/virus banking, investigational product manufacturing, storage), Quality Control Testing, and BSL3 Capabilities. The company operates as a unified CDMO offering, enabling clients to progress from early development through clinical manufacturing.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Naobios and SGS partnered to manufacture a Respiratory Syncytial Virus (RSV) challenge agent for Controlled Human Infection Model (CHIM) studies. Naobios is responsible for cGMP manufacturing of the Human Viral Challenge Agent (derived from a 2015 A-strain isolate), while SGS conducts the full clinical validation within CHIM settings, including study design, clinical execution, safety oversight, and virological assessments at its Clinical Pharmacology Unit in Antwerp, Belgium. In October 2025, 12 healthy participants were successfully inoculated demonstrating a 100% attack rate with mild, self-resolving pathology.

Strategic tierCoreTypeOthersAnnounced on2019-03-01
Description

Naobios became a subsidiary of Clean Biologics group in March 2019. Clean Biologics is a European provider of services for the Life Science industry, formed in 2018 from the collaboration between Clean Cells and ArchiMed. Naobios operates as a CDMO alongside Clean Cells (sister company), which provides in-process and release testing services to Naobios. Additional functions including Purchase, Maintenance, Building work, and Qualification are supported by the holding company.

Strategic tierCoreTypeOthers
Description

Clean Cells is Naobios' sister company under the Clean Biologics group. Naobios works in close collaboration with Clean Cells for in-process and release testing services, complementing Naobios' own quality control capabilities.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
1Yposkesi
TypeDirect peer
Description

Yposkesi is a French viral vector CDMO specializing in GMP manufacturing of AAV and lentiviral vectors for gene and cell therapy. Closely comparable to Naobios as a European-based viral CDMO serving gene therapy and vaccine developers with similar scale and customer base.

2Cobra Biologics (Charles River)
TypeBroad incumbent
Description

Cobra Biologics (now part of Charles River Laboratories) provides viral vector and plasmid DNA CDMO services for gene therapy and vaccine developers. Directly comparable to Naobios in viral vector CDMO service model, though with broader integration into a larger CRO/CDMO platform.

TypeRegional player
Description

Biological E is an Indian vaccine manufacturer that previously owned Naobios (operating it as BE Vaccines SAS until 2019). Comparable in viral vaccine manufacturing capability but serving different geographic markets (predominantly India and emerging markets) with much larger commercial-scale operations.

TypeDirect peer
Description

Vibalogics is a German-based viral vector and viral vaccine CDMO offering process development and GMP manufacturing across multiple virus types. Directly comparable to Naobios in service scope (viral CDMO), BSL2/BSL3 capability mix, and target customer profile (biotech and pharma developing gene therapies and vaccines).

TypeBroad incumbent
Description

Catalent (and its Paragon Gene Therapy unit) is a major CDMO offering viral vector and gene therapy development and manufacturing services. Comparable to Naobios in viral vector CDMO focus but with substantially larger commercial-scale capacity and global reach.

TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs with extensive viral vector and biologics manufacturing capabilities. Comparable to Naobios in offering viral and biologic process development/GMP manufacturing but at vastly greater scale, breadth, and global footprint.

TypeDirect peer
Description

Clean Cells is Naobios's sister company within the Clean Biologics group, providing biosafety and quality testing services for biological products. Highly relevant as an operational partner with overlapping customer base, complementing Naobios's manufacturing services with release testing.

TypeBroad incumbent
Description

AGC Biologics is a large global CDMO offering viral vector, cell therapy, and biologics GMP manufacturing. Comparable to Naobios as a viral/biologics CDMO serving gene therapy and vaccine sponsors but operating at significantly larger scale with broader geographic reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Naobios

Viral Biologics Contract Manufacturing (CDMO)naobios.com

Naobios is a France-based CDMO providing bioprocess development and GMP manufacturing services for virus-based products—including viral vaccines, viral vectors, oncolytic viruses, and human viral challenge agents—to pharmaceutical, biotech, academic, and public health clients.

What Naobios does

Naobios is a France-based Contract Development and Manufacturing Organization (CDMO) headquartered in Saint-Herblain near Nantes, specializing in bioprocess development and GMP-compliant contract manufacturing of virus-based products for preclinical and clinical use. The company serves pharmaceutical and biotechnology companies, academic institutions, and public health agencies worldwide, with a portfolio spanning viral vaccines (live and inactivated), viral vectors, oncolytic viruses, exosomes, and Human Viral Challenge Agents (HVCAs). Naobios operates as a subsidiary of the Clean Biologics group, alongside its sister company Clean Cells, which provides complementary in-process and release testing services.

The company's core technical platform encompasses upstream processing (USP) and downstream processing (DSP) for virus-based biologics, utilizing adherent cell-based processes (Vero, MRC5, BHK21, CEF with microcarriers, fixed bed reactors, roller bottles) and suspension cell lines (CAP, EB66, CHO). Manufacturing scales extend up to 200L in stirred tank reactors or 200m² in fixed bed bioreactors, and Naobios operates both BSL2 and BSL3 GMP suites, including a 110 sqm BSL3 facility designed per French decree and EU-GMP standards. The company has manufactured and released 36 GMP batches of HVCAs covering SARS-CoV-2, RSV, hMPV, and influenza, alongside 55+ GMP drug substance batches, and can deliver a drug product within 11 months using an in-house developed process. Regulatory credentials include ANSM pharmaceutical establishment licensing (authorization F19/219), EU-GMP certification, and authorization for GMO handling.

Naobios generates revenue through project-based B2B service contracts for bioprocess development, GMP manufacturing, quality control testing, and regulatory support, supplemented by grant funding from organizations such as the Bill & Melinda Gates Foundation. Pricing is quote-based and project-specific, depending on scope, scale, biosafety level, and regulatory requirements, and is not publicly disclosed. Business development is led by a dedicated manager conducting direct enterprise outreach, supported by content marketing (whitepapers, webinars), industry conference participation, and LinkedIn remarketing targeting pharmaceutical and biotech professionals globally.

Naobios firmographics

Firmographics
Name
Naobios
Legal name
NAOBIOS
Website
https://naobios.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Naobios is a France-based CDMO providing bioprocess development and GMP manufacturing services for virus-based products—including viral vaccines, viral vectors, oncolytic viruses, and human viral challenge agents—to pharmaceutical, biotech, academic, and public health clients.
Ownership category
akta.pro rank

Naobios industry classification

Industry
Product category
Viral Biologics Contract Manufacturing (CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Viral vaccine manufacturing
  • Bioprocess development services
  • GMP contract manufacturing
  • Viral vector production
  • Oncolytic virus CDMO

Where Naobios is headquartered

Location

Headquarters

HQ city
Saint-herblain
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Naobios business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services (CDMO): Naobios provides bioprocess development and GMP contract manufacturing services for preclinical and clinical batches of virus-based products (viral vaccines, viral vectors, oncolytic viruses, challenge agents). Revenue is generated through project-based contracts with pharmaceutical/biotech clients, academic institutions, and health agencies. The company handles process and analytical development, production of preclinical material, GMP manufacturing, QC release testing, and regulatory support under service agreements.
  2. Grant Funding: Naobios receives grant funding from foundations (e.g., Bill & Melinda Gates Foundation) to support vaccine development projects, specifically for manufacturing human viral challenge agents for CHIM studies and evaluating vaccine effectiveness in low- and middle-income countries.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Naobios product offering

Product offering

Core offering

Naobios is a GMP-certified Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and contract manufacturing services for virus-based products, including viral vaccines (live and inactivated), viral vectors, oncolytic viruses, exosomes, and Human Viral Challenge Agents. The company delivers end-to-end services spanning upstream and downstream bioprocess development, GMP manufacturing of preclinical and clinical batches, and quality control testing, with full BSL2 and BSL3 capabilities supporting manufacturing up to 200L stirred-tank or 200m² fixed-bed bioreactor scale.

Product overview

Naobios is a Contract Development and Manufacturing Organization (CDMO) providing a comprehensive suite of virus-based products and services. The product portfolio includes Live Viruses, Oncolytic Viruses, Exosomes, Inactivated Viruses, and Human Viral Challenge Agents. These products are supported by integrated services covering Bioprocess Development (USP/DSP), GMP Biomanufacturing (cell/virus banking, investigational product manufacturing, storage), Quality Control Testing, and BSL3 Capabilities. The company operates as a unified CDMO offering, enabling clients to progress from early development through clinical manufacturing.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Drug product delivery in 11 months using in-house developed process
  • +2 more outcomes

Companies that use Naobios

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Naobios technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Naobios partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • SGScoreStrategic or Co-development Partner · 9 March 2026Naobios and SGS partnered to manufacture a Respiratory Syncytial Virus (RSV) challenge agent for Controlled Human Infection Model (CHIM) studies. Naobios is responsible for cGMP manufacturing of the Human Viral Challenge Agent (derived from a 2015 A-strain isolate), while SGS conducts the full clinical validation within CHIM settings, including study design, clinical execution, safety oversight, and virological assessments at its Clinical Pharmacology Unit in Antwerp, Belgium. In October 2025, 12 healthy participants were successfully inoculated demonstrating a 100% attack rate with mild, self-resolving pathology.
  • Clean BiologicscoreOthers · 1 March 2019Naobios became a subsidiary of Clean Biologics group in March 2019. Clean Biologics is a European provider of services for the Life Science industry, formed in 2018 from the collaboration between Clean Cells and ArchiMed. Naobios operates as a CDMO alongside Clean Cells (sister company), which provides in-process and release testing services to Naobios. Additional functions including Purchase, Maintenance, Building work, and Qualification are supported by the holding company.
  • Clean CellscoreOthersClean Cells is Naobios' sister company under the Clean Biologics group. Naobios works in close collaboration with Clean Cells for in-process and release testing services, complementing Naobios' own quality control capabilities.

Scale indicators9 records

Recent moves10 records

Expansion highlights5 records

Naobios competitors and assessment

Company assessment

Direct peers

  • Yposkesi: Yposkesi is a French viral vector CDMO specializing in GMP manufacturing of AAV and lentiviral vectors for gene and cell therapy. Closely comparable to Naobios as a European-based viral CDMO serving gene therapy and vaccine developers with similar scale and customer base.
  • Vibalogics: Vibalogics is a German-based viral vector and viral vaccine CDMO offering process development and GMP manufacturing across multiple virus types. Directly comparable to Naobios in service scope (viral CDMO), BSL2/BSL3 capability mix, and target customer profile (biotech and pharma developing gene therapies and vaccines).
  • Clean Cells: Clean Cells is Naobios's sister company within the Clean Biologics group, providing biosafety and quality testing services for biological products. Highly relevant as an operational partner with overlapping customer base, complementing Naobios's manufacturing services with release testing.

Broad incumbents

  • Cobra Biologics (Charles River): Cobra Biologics (now part of Charles River Laboratories) provides viral vector and plasmid DNA CDMO services for gene therapy and vaccine developers. Directly comparable to Naobios in viral vector CDMO service model, though with broader integration into a larger CRO/CDMO platform.
  • Catalent (Paragon Gene Therapy): Catalent (and its Paragon Gene Therapy unit) is a major CDMO offering viral vector and gene therapy development and manufacturing services. Comparable to Naobios in viral vector CDMO focus but with substantially larger commercial-scale capacity and global reach.
  • Lonza Biologics: Lonza is one of the world's largest CDMOs with extensive viral vector and biologics manufacturing capabilities. Comparable to Naobios in offering viral and biologic process development/GMP manufacturing but at vastly greater scale, breadth, and global footprint.
  • AGC Biologics: AGC Biologics is a large global CDMO offering viral vector, cell therapy, and biologics GMP manufacturing. Comparable to Naobios as a viral/biologics CDMO serving gene therapy and vaccine sponsors but operating at significantly larger scale with broader geographic reach.

Regional players

  • Biological E Limited: Biological E is an Indian vaccine manufacturer that previously owned Naobios (operating it as BE Vaccines SAS until 2019). Comparable in viral vaccine manufacturing capability but serving different geographic markets (predominantly India and emerging markets) with much larger commercial-scale operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Naobios social profiles

Digital presence

Naobios compliance and trust

Trust signal

Compliance4 records

Naobios financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Naobios leadership team

Management profile

Number of profiles

Profiles5 records

Naobios funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Naobios M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Naobios

What does Naobios do?

Naobios is a GMP-certified Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and contract manufacturing services for virus-based products, including viral vaccines (live and inactivated), viral vectors, oncolytic viruses, exosomes, and Human Viral Challenge Agents. The company delivers end-to-end services spanning upstream and downstream bioprocess development, GMP manufacturing of preclinical and clinical batches, and quality control testing, with full BSL2 and BSL3 capabilities supporting manufacturing up to 200L stirred-tank or 200m² fixed-bed bioreactor scale.

Is Naobios a public or private company?

Naobios is a private company. It is classified as corporate owned and is currently operating.

When was Naobios founded?

Naobios was founded in 2005. It employs 11 to 50 people.

Where is Naobios based?

Naobios is headquartered in Saint-herblain, France, in the Europe region.

How does Naobios make money?

Two revenue lines are on record. Contract Development and Manufacturing Services (CDMO) is the primary driver. The others are grant Funding.

Who are Naobios's main competitors?

Direct peers on record are Yposkesi, Vibalogics and Clean Cells. Broad incumbents are Cobra Biologics (Charles River), Catalent (Paragon Gene Therapy), Lonza Biologics and AGC Biologics. Biological E Limited is listed as a regional player.

Does Naobios have an API?

No public API is recorded for Naobios.

What industry is Naobios in?

Naobios's product category is Viral Biologics Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 32541 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceNaobios and SGS Partner to Manufacture Respiratory Syncytial Virus (RSV) Challenge AgentNaobios and SGS have announced a partnership to manufacture a Respiratory Syncytial Virus (RSV) challenge agent for Controlled Human Infection Model (CHIM) studies, supporting the development of affordable RSV vaccines. The Human Viral Challenge Agent, produced under cGMP conditions from a 2015 A-strain isolate, was tested in October 2025 on 12 healthy participants at SGS's Clinical Pharmacology Unit in Antwerp, Belgium, demonstrating a 100% attack rate with mild, self-resolving pathology. The collaboration enables Naobios to extend its viral challenge agent manufacturing services to meet global client needs in vaccine development.The Pharma LetterNaobios and SGS partner on agents for vaccine studiesFrench contract development and manufacturing organization Naobios has partnered with Swiss testing and certification group SGS to produce a respiratory syncytial virus (RSV) challenge agent for controlled human infection model studies. The partnership is designed to accelerate vaccine development by enabling CHIM studies, which use controlled human infections to test vaccine candidates. The collaboration combines Naobios' manufacturing capabilities with SGS' testing and certification expertise.PharmiWeb.comNaobios and SGS partner to manufacture Respiratory Syncytial Virus (RSV) challenge agentNaobios and SGS announced a partnership to manufacture a Respiratory Syncytial Virus (RSV) challenge agent for use in Controlled Human Infection Model (CHIM) studies, supporting accelerated development of affordable RSV vaccines. The challenge agent is produced under cGMP conditions using a 2015 A-strain isolate that mirrors currently circulating RSV strains. In October 2025, 12 healthy participants were successfully inoculated at SGS Clinical Pharmacology Unit in Antwerp, Belgium, demonstrating a 100% attack rate with mild, self-resolving pathology, generating first-in-human proof-of-concept data.PharmiWeb.comNaobios and European Vaccine Initiative partner up to manufacture Respiratory Syncytial Virus (RSV) challenge agentNaobios and the European Vaccine Initiative announced a collaboration to manufacture an RSV challenge agent for Controlled Human Infection Model studies. The partnership, part of the Inno4Vac project, aims to accelerate RSV vaccine development, with financial terms undisclosed. The challenge agent will support early evaluation of vaccine effectiveness.NaobiosPress ReleaseNaobios, a Contract Development and Manufacturing Organization based in France, announced the receipt of a $1.87 million grant from the Bill & Melinda Gates Foundation to support vaccine development. The funding will enable Naobios to manufacture an Omicron variant SARS-CoV-2 viral challenge agent for Controlled Human Infection Model (CHIM) studies aimed at accelerating the creation of mucosal vaccines. This project involves three years of stability testing and supports the broader goal of deploying effective vaccines to Low-to-Middle Income Countries.Tech.euNaobios awarded €1.7M grant for vaccine development by Bill & Melinda Gates foundationNaobios announced it has received a €1.7M grant from the Bill & Melinda Gates Foundation to support vaccine development. The grant will help Naobios manufacture a human viral challenge agent aimed at evaluating vaccine effectiveness and accelerating the vaccine development process. This initiative focuses on creating low-cost, effective mucosal vaccines to prevent respiratory virus transmission, particularly in low to middle-income countries.FinSMEsNaobios Receives $1.87M GrantNaobios, a Nantes-based CDMO, received a $1.87 million grant from the Bill & Melinda Gates Foundation to evaluate vaccine effectiveness and accelerate development processes. The funding supports the company's efforts in bioprocess development and GMP production of clinical batches for viral vaccines and related agents.